Jiedu Xiaozheng Yin Inhibits the Progression of Colitis Associated Colorectal Cancer by Stimulating Macrophage Polarization Towards an M1 Phenotype via the TLR4 Pathway

• Published in: Integrative cancer therapies 2024-01, Vol.23, p.15347354241247061-15347354241247061
• Main Authors: Liu, Haiqin, Yan, Shuo, Yang, Ruiming, Huang, Caidi, Guo, Kangyue, Wang, Shi, Huang, Yunmei, Shen, Dongyi, Lin, Ying, Cao, Zhiyun, Zhong, Hangyan, Lin, Jiumao, Chen, Xuzheng
• Format: Article
• Language: English
• Subjects: Animals; Colitis-Associated Neoplasms - drug therapy; Colitis-Associated Neoplasms - metabolism; Drugs, Chinese Herbal - pharmacology; Drugs, Chinese Herbal - therapeutic use; Interleukin-10 - metabolism; Interleukin-6 - metabolism; Macrophages - drug effects; Macrophages - metabolism; Mice; Phenotype; Toll-Like Receptor 4 - drug effects; Toll-Like Receptor 4 - metabolism; Tumor Necrosis Factor-alpha - metabolism
• ISSN: 1534-7354; 1552-695X
• DOI: 10.1177/15347354241247061

To investigate the effect of Jiedu Xiaozheng Yin (JXY) on the polarization of macrophages in colitis-associated colon cancer (CAC). An orthotopic model of CAC was established to monitor changes in the pathological state of mice. Colon length, number of colon tumors were recorded, and indices for liver, spleen, and thymus were calculated. Hematoxylin and eosin (H&E) staining was employed to observe intestinal mucosal injury and tumor formation. Immunohistochemistry (IHC) staining was utilized to investigate the effect of JXY on M1 and M2 polarization of macrophages in the colonic mucosa of CAC mice. For in vitro experiments, RT-qPCR (Reverse Transcription-quantitative PCR) and flow cytometry were used to observe the effect of JXY on various M1-related molecules such as IL-1β, TNF-α, iNOS, CD80, CD86, and its phagocytic function as well as M2-related molecules including Arg-1, CD206, and IL-10. Subsequently, after antagonizing the TLR4 pathway with antagonists (TAK242, PDTC, KG501, SR11302, LY294002), the expression of IL-6, TNF-α, iNOS, and IL-1β mRNA were detected by RT-qPCR. In vivo experiments, the results showed that JXY improved the pathological condition of mice in general. And JXY treatment decreased the shortening of colon length and number of tumors as compared to non-treated CAC mice. Additionally, JXY treatment improved the lesions in the colonic tissue and induced a polarization of intestinal mucosal macrophages towards the M1 phenotype, while inhibiting polarization towards the M2 phenotype. In vitro experiments further confirmed that JXY treatment promoted the activation of macrophages towards the M1 phenotype, leading to increased expression of IL-1β, TNF-α, iNOS, CD80, CD86, as well as enhanced phagocytic function. JXY treatment concomitantly inhibited the expression of M2-phenotype related molecules Arginase-1 (Arg-1), CD206, and IL-10. Furthermore, JXY inhibited M1-related molecules such as IL-6, TNF-α, iNOS, and IL-1β after antagonizing the TLR4 pathway. Obviously, JXY could exhibit inhibitory effects on the development of colon tumors in mice with CAC by promoting M1 polarization through TLR4-mediated signaling and impeding M2 polarization of macrophages.